Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.63 |
| ▸ | ITGAV | P06756 | 20/20 | 0.63 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.63 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366686 | 0.91 | ITGB3 (0.75) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL6016209 | 0.87 | ITGB3 (0.84) | ITGB3ITGAVITGA2B | |
| SCHEMBL4838471 | 0.86 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7223767 | 0.85 | ITGB3 (0.54) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL6829399 | 0.82 | ITGB3 (0.50) | ITGB3ITGAVITGA2B | |
| SCHEMBL6831996 | 0.81 | ITGB3 (0.62) | ITGB3ITGAVITGA2B | |
| SCHEMBL7651509 | 0.80 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL5176163 | 0.80 | SYK (0.49) | — | |
| SCHEMBL7232314 | 0.80 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7406088 | 0.79 | ITGB3 (0.65) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348333-B2 | Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. | 2008-01-24 | — | — | US | disclosed |
| EP-0820991-B1 | Cycloalkyl derivatives as bone resorption inhibitors and vitronectin receptor antagonists | HOECHST AG (DE) | 2007-08-29 | — | — | EP | disclosed |
| US-20030050314-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. | 2003-03-13 | — | — | US | disclosed |
| US-6399620-B1 | (2S)-2-(1-ADAMANTYL-METHYLOXYCARBONYLAMINO)-3-(4-(3-GUANIDINO -CARBONYL-PROPYLOXY)PHENYL)PROPIONIC ACID; ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; CARDIOVASCULAR DISORDERS | AVENTIS PHARMA S.A. (DE) | 2002-06-04 | — | — | US | disclosed |
| EP-0820991-A2 | Cycloalkyl derivatives as bone resorption inhibitors and vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | ADGRF1, ADGRE5, CALCR | ITGB3 536/4885ITGAV 737/4885ITGA2B 379/4885 |
| US-20030050314-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | ADGRF1, CALCRL, ADGRE5 | ITGB3 545/4885ITGAV 684/4885ITGA2B 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.